FDA’s Accelerated Approval Pathway Drives Momentum for Intractable, Fatal Diseases
With notable market withdrawals and failed confirmatory studies, the accelerated approval pathway has come under fire recently, but its naysayers discount one very important byproduct of the program: therapeutic momentum. Enacted in 1992 in response to the …